ImmuPharma (LON:IMM) Shares Up 34.1% - Time to Buy?

Key Points

• ImmuPharma shares surged 34.1% during mid-day trading, reaching a high of GBX 11.50 ($0.16) before settling at GBX 10.81 ($0.15), significantly rising from the previous closing price of GBX 8.06 ($0.11).
• The company has a market capitalization of £54.02 million and a notably high P/E ratio of -1,214.61, indicating substantial volatility and potential investor risk.
• ImmuPharma is a biopharmaceutical company specializing in peptide-based therapeutics, particularly for autoimmune diseases, with its lead program being Lupuzor™, targeting Lupus treatment.

ImmuPharma plc (LON:IMM - Get Free Report) shares rose 34.1% during mid-day trading on Tuesday . The company traded as high as GBX 11.50 ($0.16) and last traded at GBX 10.81 ($0.15). Approximately 57,593,953 shares traded hands during mid-day trading, an increase of 656% from the average daily volume of 7,620,919 shares. The stock had previously closed at GBX 8.06 ($0.11).

ImmuPharma Trading Up 34.1%

The company has a market capitalization of £54.02 million, a P/E ratio of -1,214.61 and a beta of 1.53. The company has a 50 day moving average price of GBX 2.38 and a 200 day moving average price of GBX 2.70.

ImmuPharma (LON:IMM - Get Free Report) last posted its quarterly earnings results on Wednesday, August 6th. The company reported GBX (0.38) earnings per share for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 131.41%. As a group, sell-side analysts forecast that ImmuPharma plc will post -339.0000022 EPS for the current fiscal year.

About ImmuPharma

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.